Guggenheim Initiates Coverage On Coherus Oncology with Buy Rating, Announces Price Target of $12

Benzinga Newsdesk www.benzinga.com Positive 63.0%

Neg 0% Neu 0% Pos 63%

Guggenheim initiates coverage on Coherus Oncology (NASDAQ:CHRS) with a Buy rating and announces Price Target of $12.

Comments

No comments yet. Be the first!